Oric Pharmaceuticals, Inc. ORIC EBITDA

EBITDA at other companies

PfizerPFE

$4.78B+8.6%

ArriVent BioPharma, Inc.AVBP

-$46.67M+30.9%

CG OncologyCGON

-$85.55M-76.1%

Olema Pharmaceuticals, Inc.OLMA

-$57.87M-66.5%

Stoke Therapeutics, Inc.STOK

-$52.98M-147%

Ionis PharmaceuticalsIONS

-$98.16M-169%

FAQ

What is Oric Pharmaceuticals, Inc.'s EBITDA?

Oric Pharmaceuticals, Inc. (ORIC) reported EBITDA of -$39.35M in Q1 2026.

How has Oric Pharmaceuticals, Inc.'s EBITDA changed year-over-year?

Oric Pharmaceuticals, Inc.'s EBITDA decreased by 21.4% year-over-year, from -$32.42M to -$39.35M.

What is the long-term trend for Oric Pharmaceuticals, Inc.'s EBITDA?

Over 4 years (2021 to 2025), Oric Pharmaceuticals, Inc.'s EBITDA has grown at a 16.1% compound annual growth rate (CAGR), from -$77.97M to -$141.78M.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.